The in-hospital mortality (9.5% vs 3.3%, p<0.001) and at 6 months (15.6% vs 6.6%, p<0.001) were also higher, however, the presence of de novo AF was not an independent predictor of these events. Most P were discharged in SR (n=134) and without anticoagulant therapy (n=117). 95 patients with de novo AF were followed for a median period of 690 days and it was observed the occurrence of ischemic stroke/systemic embolism in 9 P (9.5%), but only one was under oral anticoagulation.
Background Radiofrequency catheter ablation (RFCA) is increasingly used in the management of ventricular tachycardia (VT) in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC/D) but it is associated with a high level of recurrences.
Objective To determine predictors associated with VT recurrence after RFCA in ARVC/D.
Methods This study included 85 consecutive patients referred to the Pitié Salpêtrière Hospital (Paris, France) who underwent a total of 149 RFCA procedures between 2000 and 2010. Predictors of recurrence of VT following RFCA were assessed by Cox regression.
Results
The mean age of the cohort was 36±13 years, 74 (87.1%) were men and 80 (95.2%) were proband. 70 (83.3%) experienced spontaneous VT before diagnosis. 30 (58.8%) patients required ≥2 procedures. In 13 (10.7%) patients, RFCA was performed through epicardial access. Over a mean follow-up of 114±60 months, the overall freedom from VT of the 149 procedures was 79%, and 56%, at 1 and 5 years, respectively. The presence of an epsilon wave and of right ventricular (RV) dysfunction (defined by RV angiography ejection fraction <40% or right area fractional change <35% by TTE) were associated with higher level of recurrences on multivariate analysis. The cumulative freedom from VT ( Figure) in patients without RV dysfunction nor epsilon wave was 86% at 1 and 5 years, which was significantly longer than those without (76% and 47% respectively, P=0.003).
Conclusion Absence of RV dysfunction or of an epsilon wave are strongly associated with higher success after VT RFA in ARVC/D. Patients without those risk factors should therefore be considered as good candidates for VT ablation. Background Atrial arrhythmias (AA) are observed frequently early after lung transplant and also late after the surgery. Several predictive factors of post-operative AA after lung transplant have been already identified whereas those of late AA are still not known. Whether AA after lung transplant impacts mortality and the optimal strategy of rhythm management are still debated.
The Purpose of the study was to assess in a large cohort of lung transplanted patients the incidence of AA early and late after surgery, their predictive factors and their impact on mortality.
Methods and results
We included 271 consecutive patients single or double lung-transplanted over a 9-years period in a large French center. We collected baseline clinical, surgery and post-operative data. The follow-up was 2,9±2,4 years. 33% patients developed post-operative AA. Age (HR=2, 35; CI [1, 24] ) and chronic obstructive pulmonary disease (HR=1,028; CI [1,12-4,03]) were independant predictive factors of post-operative AA. Late AA occurred 2,2±2,7 years after transplant in 8.8% of the patients. Systolic pulmonary arterial pressure was the only independent predictive factor of late AA (HR=1,028; CI [1,001; 1,056]). Double lung transplant was associated with long term freedom from AF compared with single transplant (p=0,05) whereas the Kaplan-Meier curve for the development of late atrial flutter was similar in single and double lung transplant. Early and late AA after surgery showed no impact on mortality. Bilateral lung transplant was associated with a better survival.
Conclusion Post-operative AA after lung transplantation are common with good outcome and contrast with the low occurrence of late organized AA. Double lung transplantation protects against AF but not AFL. Underlying electrophysiological mechanisms may explain these observations. Predictive factors of early and late AA after transplantation are different. Nevertheless these AA do not impact mortality after lung transplant (figure next page).
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